Insights from MARIPOSA: Impressions of the Intracranial Data
Panelists discuss how intracranial progression-free survival (PFS) and duration of response (DoR) influence treatment decisions, highlighting the significance of intracranial data in differentiating this regimen within the treatment landscape, its potential impact on brain metastases management, and the role of radiation therapy in clinical practice.
Video content above is prompted by the following:
Intracranial PFS and DoR Insights
The regimen appears to improve intracranial activity, potentially enhancing PFS and DoR in brain metastases. This aligns with secondary end point findings from trials such as ADAURA, in which brain-related outcomes were a focus.
Impact on Treatment Decisions
The presence of intracranial efficacy may influence the decision to use this combination therapy, though definitive comparisons with other regimens are challenging due to sample size limitations. Physicians weigh this factor alongside survival benefits and toxicity considerations.
Differentiation From Other Treatments
While the data are promising, the trial lacks a sufficiently large sample to definitively differentiate this regimen from others. The role of radiation therapy remains limited, mainly reserved for large or critically located brain tumors.
Brain Metastases Management
Most patients with small or multiple metastases are managed without upfront radiation, as systemic therapy shows efficacy. Only around 10% to 15% of patients receive radiation, typically for lesions greater than or equal to 2 cm or those in high-risk locations.
Overall, while the data are reassuring for intracranial efficacy, broader comparisons and further studies are needed for conclusive differentiation.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
